During current crisis diagnostic labs are one of the most affected. With increase in no of cases Govt has allowed more pvt lab testing. As per the latest ICMR report no of labs approved among listed players as follows:
Metropolis: 3 (Mumbai,Pune,Chennai)
Dr Lal path: 2 ( Delhi,Kolkata)
Thyrocare :1 (Mumbai)
COVID_19_Testing_Labs_03052020.pdf (547.9 KB) (complete list of labs)
As per feedback 2 weeks back Metropolis was doing almost 500 Covid test per day and that must have been increased now. What extent these tests can contribute to revenue (at fixed price ? Max of Rs.4,500 per test) ,is it profitable to labs is question mark. Going by MD commentary at govt fixed prices these tests are not loss making. If any VP member working in diagnostic industry can through more light on price with various state Govts,method of payment collection…etc will be helpful.
Going by FICCI report on covid impact on diagnostic sector things doesn’t look good:
Discl: invested :Metropolis,tracking positions with Lal path lab